States in India have about 13 million Kovid-19 vaccine supplements – about 7.8 million Kovild and 5.7 million Kovaxins – about 10 million more in the pipeline for distribution between states in the coming weeks, according to figures shown by HT on Sunday Was reviewed.
According to government data obtained by HT, as of April 18, a total of 144 million doses were supplied to all states and union territories, approximately 127 million doses of covicillin and 17 million doses of the covaxine vaccine.
Amidst the state’s allegations that the vaccines are in short supply, the Center says there is no shortage in the country. “Manufacturers are supplying their optimum capacity and the government. They are simultaneously emphasizing their abilities which will be visible by June.
Currently India is administering two vaccines – Kovishield and Kovaxin – a nationwide vaccination campaign against infectious disease started on 16 January. The Drug Controller General of India (DCGI) last week approved the Kovid-19 vaccine developed by Russia’s Gamalaya Research Institute, Sputnik. V, for emergency use in India, a day after the Regulatory Subject Expert Committee (SEC) recommended that there was sufficient data to give the vaccine to the Emergency Use Authority. The first local supply of the Russian vaccine is expected by July.
Kovishid is an Oxford-AstraZeneca vaccine produced locally by the Serum Institute of India (SII), and Kovaxin is co-developed by Bharat Biotech International Limited and the Indian Council of Medical Research.
Of the 144 million doses supplied to the states, a total of 123 million doses have been consumed since the introduction of the nationwide Kovid-19 vaccination. Of these, Kovishield supplements are about 110 million and Kovaxin supplements are about 11 million, government data show.
“The companies have fixed capacity, and as I said, they are producing 100% for the government, so there are no supply issues,” he said on condition of anonymity.
Another government official, who spoke on condition of anonymity, said: “Supply is not an issue; The focus of the government is to ensure vaccination to the maximum eligible beneficiaries at the earliest. ”
The Union Ministry of Health and Family Welfare has also written a letter to the states on Sunday asking them to ensure movement restrictions imposed by the government for Kovid-19 control so that vaccination practice is not adversely affected.
Manohar Agnani said, “It is advised that Kovid-19 vaccination services should not be affected by Kovid-19 curfew / lockdown, and movement of beneficiaries from Kovid-19 vaccination centers should not be restricted.” Secretary, Ministry of Health in his letter to the states.
Experts said that with the rapid increase in cases, vaccination would be an important intervention to reduce the number in the long run.
“We do not have enough evidence to support whether these vaccines are effective in preventing transmission; However, we know that they inhibit the progression of the disease to a serious level. If we continue the minor version of the infection for some time, it may die over time, which is why vaccination is important, ”Dr. K Srinath Reddy, Founder, Public Health Foundation of India said.